Related Experiment Video

Updated: Dec 19, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.4K

FDA Approves Selpercatinib; Pralsetinib May Soon Follow

    Cancer Discovery
    |June 5, 2020
    PubMed

    Insights

    The FDA approved selpercatinib, a targeted therapy for RET-altered non-small cell lung cancer (NSCLC) and thyroid cancer. Pralsetinib, another RET inhibitor, is also under review, showing promise for brain metastases in NSCLC.

    Area of Science:

    • Oncology
    • Pharmacology
    • Genetics

    Background:

    • Non-small cell lung cancer (NSCLC) and thyroid cancer can harbor RET alterations.
    • Targeted therapies offer new treatment avenues for cancers with specific genetic mutations.

    Purpose of the Study:

    • To report the FDA approval of selpercatinib for RET-altered NSCLC and thyroid cancer.
    • To highlight the development and potential of pralsetinib, another RET inhibitor, for NSCLC treatment.

    Main Methods:

    • Review of clinical trial data and regulatory submissions for selpercatinib and pralsetinib.
    • Analysis of drug efficacy, particularly in patients with brain metastases.

    Main Results:

    • Selpercatinib received FDA approval as the first targeted therapy for RET-altered NSCLC and certain thyroid cancers.
    • Pralsetinib has been submitted for approval and demonstrated effectiveness in treating brain metastases in NSCLC patients.

    Conclusions:

    • Targeted inhibition of RET alterations represents a significant advancement in treating specific NSCLC and thyroid cancers.
    • Both selpercatinib and pralsetinib show promise, offering new hope for patients, including those with brain metastases.

    More Related Videos

    Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma06:08

    Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

    Published on: June 2, 2023

    2.2K
    Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

    Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

    Published on: April 26, 2024

    3.6K

    Related Concept Videos

    FDA Approved Drugs: Changes to Approved Drugs01:26

    FDA Approved Drugs: Changes to Approved Drugs

    Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
    137
    Clinical Trials: Overview01:11

    Clinical Trials: Overview

    Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
    4.4K
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    5.8K
    Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

    Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

    Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
    TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
    367